The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis.
The serum erythropoietin (EPO) concentration in patients with myelodysplasia (MDS) varies widely at similar hemoglobin concentrations, although the reasons for this variation are unclear. We have studied the pharmacokinetics of an i.v. bolus of recombinant human EPO in ten subjects with myelodysplasia. Basal serum EPO concentration varied from 210 to 5984 mU/ml. Plasma half-time clearance (t1/2) varied from 3.9 to 20.0 h. A significant positive correlation was found between t1/2 and basal EPO concentration. An increase in immature peripheral blood reticulocytes was found on days 1 and 2 after EPO treatment; this may represent either an effect on hemopoiesis or on reticulocyte release from the bone marrow.
Bowen
D
D
Department of Haematology, University of Wales College of Medicine, Cardiff, UK.
Ehmer
B
B
Neubert
P
P
Lewis
T
T
Jacobs
A
A
D000368:Aged; D000369:Aged, 80 and over; D004920:Erythropoiesis; D004921:Erythropoietin / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000097:blood*; D012313:RNA / Q000097:blood; D011994:Recombinant Proteins / Q000493:pharmacokinetics / Q000494:pharmacology
D011994:Recombinant Proteins; D004921:Erythropoietin; D012313:RNA